CRISPR

CRISPR sequences were first identified in 1987 in Escherichia coli by Yoshizumi Ishino and colleagues, who noticed unusual repetitive DNA elements downstream of the iap gene.¹ Later, in 2005, three independent research groups recognized that the spacer sequences between repeats matched phage and plasmid DNA, suggesting a role in adaptive immunity.² The system works by integrating short fragments of foreign DNA into the CRISPR locus, which are then transcribed and processed into CRISPR RNAs (crRNAs) that guide Cas proteins to cleave matching foreign DNA on subsequent exposure.³ This provides a heritable, sequence-specific defense mechanism that is remarkably widespread, present in about 40% of sequenced bacterial genomes and nearly all archaea.⁴

The most widely used CRISPR system is the type II system from Streptococcus pyogenes, which employs the Cas9 protein. In its natural context, Cas9 forms a complex with two RNAs: a crRNA that contains the spacer sequence and a trans-activating crRNA (tracrRNA) that is partially complementary to the crRNA. In 2012, Jennifer Doudna and Emmanuelle Charpentier demonstrated that this two-RNA structure could be simplified into a single guide RNA (sgRNA) for programmable DNA cleavage.⁵ The Cas9-sgRNA complex recognizes a protospacer adjacent motif (PAM) sequence (5'-NGG-3' for SpCas9) immediately downstream of the target site, unwinds the DNA, and induces a double-strand break. This break can be repaired by error-prone non-homologous end joining (NHEJ) to create gene knockouts, or by homology-directed repair (HDR) to introduce specific mutations or insertions.⁶

CRISPR-Cas9 has revolutionized genetic engineering due to its simplicity, efficiency, and versatility. It has been applied to create animal models of human disease, engineer crops with improved traits, and develop gene therapies for genetic disorders such as sickle cell disease and beta-thalassemia.⁷ In 2020, the Nobel Prize in Chemistry was awarded to Doudna and Charpentier for their pioneering work.⁸ Beyond Cas9, other Cas variants like Cas12a (Cpf1) and base editors have expanded the toolkit, enabling more precise edits and reduced off-target effects.⁶ Clinical trials are underway for various conditions, including cancer immunotherapy and inherited blindness, with some therapies already approved in several countries.

The power of CRISPR to edit human germline cells raises profound ethical and safety concerns. In 2018, He Jiankui announced the creation of gene-edited twins, sparking international condemnation and calls for a moratorium on heritable genome editing.⁹ Regulatory frameworks vary globally: some countries ban germline editing, while others permit research with restrictions. The World Health Organization has established an expert advisory committee to develop global governance standards.¹⁰ Additionally, off-target effects and mosaicism remain technical challenges that must be addressed to ensure safe clinical application.

Beyond genome editing, CRISPR systems have been repurposed for diverse applications. For example, CRISPR interference (CRISPRi) uses a catalytically dead Cas9 (dCas9) to repress gene expression without cutting DNA, enabling reversible gene silencing.⁶ CRISPR can also be used for RNA targeting with Cas13, which has been developed as a diagnostic tool for detecting viral RNA, including SARS-CoV-2, in the SHERLOCK platform.¹¹ In agriculture, CRISPR has been used to create hornless cattle and disease-resistant pigs, and to improve the shelf life of mushrooms and other produce.¹² Additionally, some bacteria use CRISPR to store memories of past infections, and the system has been implicated in gene regulation and genome evolution beyond immunity.

Cas9

A CRISPR-associated protein that acts as a molecular scissor to cut DNA at specific sites.

crRNA

CRISPR RNA, a short RNA molecule that guides Cas proteins to complementary DNA sequences.

tracrRNA

Trans-activating crRNA, a non-coding RNA that pairs with crRNA to form a functional guide in type II systems.

PAM

Protospacer adjacent motif, a short DNA sequence required for Cas9 recognition and cleavage.

NHEJ

Non-homologous end joining, a DNA repair pathway that often introduces insertions or deletions.

HDR

Homology-directed repair, a DNA repair pathway that uses a template to introduce precise edits.